Mitrix Bio is a leading company in the field of mitochondrial transplantation, focusing on producing large amounts of mitochondria for potential transplantation. Research indicates that replacing mitochondria in aged tissues can have significant benefits for health and organ function. This innovative approach holds promise for extending lifespan and improving quality of life.
In an exciting development, Mitrix Bio has announced “The 130-Year-Old-Lifespan Trials,” aiming to break the current “Lifespan Barrier” of 122 years. Volunteers, predominantly in their 70s and 80s, will undergo treatments designed to extend their lifespans to 130 years while maintaining the health and vitality of individuals half their age. The initial phase of the trial will focus on astronauts, former astronauts, and children with premature aging diseases.
The groundbreaking technique of Bioreactor-Grown Mitochondrial Transplantation, developed by Mitrix Bio, has shown promising results in animal studies, accelerating healing, boosting immunity, and potentially prolonging lifespan. With a team of top scientists on board, the company is gearing up for rigorous human trials to validate the effectiveness of this cutting-edge technology in achieving the ambitious goal of a 130-year lifespan.
Link: https://www.linkedin.com/posts/activity-7181774280462938112-oLbY
